SEC Filing

ZYMOGENETICS INC filed this Form 8-K on October 27, 2008.

total pages: 3

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

October 27, 2008

Date of Report

(Date of earliest event reported)

ZYMOGENETICS, INC.

(Exact Name of Registrant as Specified in Charter)

Washington

000-33489

91-1144498

(State or Other Jurisdiction

of Incorporation)

(Commission File No.)

(IRS Employer

Identification No.)

1201 Eastlake Avenue East, Seattle, Washington 98102-3702

(Address of Principal Executive Offices, including Zip Code)

(206) 442-6600

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01.

Regulation FD Disclosure.

On October 27, 2008, Merck Serono announced that it was discontinuing the study in lupus nephritis in the ongoing Phase II/III systemic lupus erythematosus (SLE) atacicept program. The study combining mycophenolate mofetil, corticosteroids and atacicept in patients with kidney disease had been initiated in December 2007. The observation of an increased risk for severe infection led to the discontinuation. This observation was likely the result of the underlying significant disease activity and the concomitant use of several immunosuppressive medications. The ongoing atacicept programs in generalized SLE, rheumatoid arthritis, multiple sclerosis and hematological malignancies are continuing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ZYMOGENETICS, INC.

Dated: October 27, 2008	By	/s/ James A. Johnson
		James A. Johnson
		Executive Vice President,
		Chief Financial Officer